Intermittent and continuous imatinib in a human GIST xenograft model carrying KIT exon 17 resistance mutation D816H

Acta Oncologica

Volumn 52, Issue 4, 2013, Pages 776-782

  Revheim, Mona Elisabeth ^a,b   Kristian, Alexandr ^b,c   Malinen, Eirik ^c   Bruland, Oyvind Sverre ^b,c   Berner, Jeanne Marie ^c   Holm, Ruth ^c   Joensuu, Heikki ^d   Seierstad, Therese ^a,e  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e UNIVERSITY OF SOUTH EASTERN NORWAY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER; GLUCOSE TRANSPORTER 2; GLUCOSE TRANSPORTER 3; GLUCOSE TRANSPORTER 4; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMATINIB;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; BLOOD VOLUME; CANCER SIZE; CONTROLLED STUDY; ESOPHAGUS PERFORATION; EXON; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; INTERNALIZATION; METABOLIC RATE; MITOSIS INDEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL MODEL; CANCER RESISTANCE; COMPARTMENT MODEL; IMMUNOHISTOCHEMISTRY; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; XENOGRAFT;

AMINO ACID SUBSTITUTION; ANIMALS; ANTINEOPLASTIC AGENTS; ASPARTIC ACID; BENZAMIDES; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HISTIDINE; HUMANS; MICE; MICE, NUDE; MUTATION, MISSENSE; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84875966135     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2013.770920     Document Type: Article

References (25)

1. Miettinen M, Lasota J. G astrointestinal stromal tumors (GISTs): Defi nition, occurrence, pathology, differential diagnosiSand molecular genetics. Pol J Pathol 2003; 54: 3-24.
2. Hirota S, I sozaki K, M oriyama Y, H ashimoto K, N ishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-80.
3. Rubin BP, S inger S, Tsao C, D uensing A, L ux ML, R uiz R, et al. KIT activation iSa ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001; 61: 8118-21.
4. Joensuu H, R oberts P J, Sarlomo-Rikala M, A ndersson L C, Tervahartiala P, Tuveson D, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052-6.
5. Blanke C D, Demetri G D, v on M M, H einrich M C, E isenberg B, Fletcher JA, et al. Long-term results from a randomized phase II trial of standard versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008; 26: 620-5.
6. Gramza AW, C orless C L, H einrich M C. Resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumors. Clin Cancer Res 2009; 15: 7510-8.
7. Revheim ME, Roe K, Bruland OS, Bach-Gansmo T, Skretting A, Seierstad T. Monitoring the effect of targeted therapies in a gastrointestinal stromal tumor xenograft using a clinical PET/CT. Mol Imaging Biol 2011; 13: 1234-40.
8. Shinto A, N air N, D utt A, B aghel NS. E arly response assessment in gastrointestinal stromal tumors with FDG PETscan 24 hourSafter a single dose of imatinib. Clin Nucl Med 2008; 33: 486-7.
9. Roe K, A leksandersen T B, K ristian A, N ilsen LB, S eierstad T, Qu H, et al. Preclinical dynamic 18F-FDG. Acta Oncol 2010; 49: 914-21.
10. Revheim ME, S eierstad T, B erner JM, B ruland OS, R oe K, Ohnstad HO, et al. Establishment and characterization of a human gastrointestinal stromal tumour (GIST) xenograft in athymic nude mice. Anticancer Res 2009; 29: 4331-6.
11. Heinrich M C, C orless C L, Blanke C D, Demetri GD, Joensuu H, Roberts PJ, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006; 24: 4764-74.
12. National Comprehensive Cancer Network. C linical practice guidelines in oncology. Soft tissue sarcoma. [2]. 2012. Ref Type: Data File.
13. Blay JY, L e CA, R ay-Coquard I, B ui B, D uffaud F, Delbaldo C, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: The French Sarcoma Group. J Clin Oncol 2007; 25: 1107-13.
14. Le CA, R ay-Coquard I, B ui BN, A deniSa, R ios M, B ertucci F, et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: An open-label multicentre randomised phase 3 trial. Lancet Oncol 2010; 11: 942-9.
15. Euhus D M, H udd C, LaRegina M C, J ohnson F E. T umor measurement in the nude mouse. J Surg Oncol 1986; 31: 229-34.
16. Qi J, L eahy RM, C herry SR, C hatziioannou A, F arquhar TH. High-resolution 3D Bayesian image reconstruction using the microPETsmall-animal scanner. Phys Med Biol 1998; 43: 1001-13.
17. Qi J, L eahy RM. Resolution and noise properties of MAP reconstruction for fully 3-D PET. IEEE Trans Med Imaging 2000; 19: 493-506.
18. Kamasak ME, B ouman CA, M orris ED, Sauer K. D irect reconstruction of kinetic parameter images from dynamic PET data. IEEE Trans Med Imaging 2005; 24: 636-50.
19. Liegl B, K epten I, L e C, Z hu M, Demetri GD, H einrich MC, et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol 2008; 216: 64-74.
20. Mullani NA, H erbst RS, O'Neil RG, G ould KL, B arron BJ, Abbruzzese JL. Tumor blood fl ow measured by PET dynamic imaging of fi rst-pass 18F-FDG uptake: A comparison with 15O-labeled water-measured blood fl ow. J Nucl Med 2008; 49: 517-23.
21. Godoy A, U lloa V, R odriguez F, Reinicke K, Y anez A J, G arcia ML, et al. Differential subcellular distribution of glucose transporters GLUT1-6 and GLUT9 in human cancer: Ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues. J Cell Physiol 2006; 207: 614-27.
22. Yamamoto T, Seino Y, Fukumoto H, Koh G, Yano H, Inagaki N, et al. Over-expression of facilitative glucose transporter genes in human cancer. Biochem Biophys Res Commun 1990; 170: 223-30.
23. Gogvadze V, O rrenius S, Z hivotovsky B. M itochondria in cancer cells: What is so speciaLabout them? Trends Cell Biol 2008; 18: 165-73.
24. Prenen H, Stefan C, Landuyt B, V ermaelen P, Debiec-Rychter M, Bollen M, et al. Imatinib mesylate inhibits glucose uptake in gastrointestinal stromal tumor cells by downregulation of the glucose transporters recruitment to the plasma membrane. Am J Biochem Biotechnol 2005; 1: 95-102.
25. Tarn C, S korobogatko Y V, T aguchi T, E isenberg B, v on MM, Godwin AK. Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKTsignaling dependent and independent mechanisms. Cancer Res 2006; 66: 5477-86.